Emcure Pharmaceuticals growth ratios

Per cent unless marked ×
Tap a line for its trendFY26Mar 2026
+16.6%
+26.5%
+33.0%
+33.0%
+33.9%
+16.8%
+7.2%
+10.8%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

EMCURE₹1,865.00

Emcure Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersMANKINDALKEMTORNTPHARMERISGRANULESCONCORDBIOINDGNCAPLIPOINTMcap ₹35,359 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+16.6—
EBITDA Growth—+26.5—
EBIT Growth—+33.0—
Net Income Growth—+33.0—
EPS Growth—+33.9—
Total Assets Growth—+16.8—
Total Equity Growth—+7.2—
Cash from Operations Growth—+10.8—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.